Research & Development

Developer and supplier of critical raw materials Biosynth, has opened the doors to its Biosynth Biological Technology site in Suzhou, China.

Located within the Lifebay innovation and technology park, the site contains new state-of-the-art facilities – including a bio-lab – that can significantly increase the company’s offerings in the region. Two key areas that the new site promises to develop upon are improving the capabilities of internal project development initiatives, and the development and supply of materials for the domestic Chinese life sciences market.

“We are thrilled to be formally opening Biosynth Biological Technology. This facility represents our dedication to innovation and excellence and adds a crucial production site for internal materials as well as acting as a distribution and handling hub for our customers in the region,” said Dr Thomas Eisele, chief operations officer.

Chief commercial officer Philip Noone added, “Through our new Lifebay facility in Suzhou, Biosynth will serve in-vitro diagnostics companies across China directly, with our comprehensive biologics, chemicals and complex peptides offering. Our new site will allow us for the first time in our history to offer our unique diagnostic solutions for infectious diseases, oncology and autoimmunity targeting emerging pathogens.”

Alessandra Vismara, general manager for China, also commented, “This has been a significant project to build and equip this facility. As part of the next phase, we will be commissioning our biosafety level two laboratories, which means that we can handle and supply even more biological diagnostic tools. Enzyme development and production for local customers will complete the portfolio of these facilities.”